Toxicities
| Characteristic . | Value (n = 10) . | % . |
|---|---|---|
| Toxicities | ||
| Maximum grade CRS | ||
| 0 | 2 | 20 |
| 1 | 6 | 60 |
| 2 | 2 | 20 |
| 3 | 0 | 0 |
| 4 | 0 | 0 |
| Maximum grade ICANS | ||
| 0 | 7 | 70 |
| 1 | 2 | 20 |
| 2 | 0 | 0 |
| 3 | 1 | 10 |
| 4 | 0 | 0 |
| HLH | ||
| Yes | 0 | 0 |
| No | 10 | 100 |
| Tocilizumab | ||
| Yes | 5 | 50 |
| No | 5 | 50 |
| Steroid use | ||
| Yes | 5 | 50 |
| No | 5 | 50 |
| Anakinra | ||
| Yes | 0 | 0 |
| No | 10 | 100 |
| Delayed Parkinsonian neurotoxicity | ||
| Yes | 0 | 0 |
| No | 10 | 100 |
| Delayed non-Parkinsonian neurotoxicity | ||
| Yes∗ | 2 | 20 |
| No | 8 | 80 |
| Treatment of delayed neurotoxicity | ||
| Steroids | 1 | 10 |
| Steroids followed by pembrolizumab (PML due to JC virus),17 followed by investigational therapy on clinical trial | 1 | 10 |
| Infections | ||
| Yes | 5 | 50 |
| No | 5 | 50 |
| Characteristic . | Value (n = 10) . | % . |
|---|---|---|
| Toxicities | ||
| Maximum grade CRS | ||
| 0 | 2 | 20 |
| 1 | 6 | 60 |
| 2 | 2 | 20 |
| 3 | 0 | 0 |
| 4 | 0 | 0 |
| Maximum grade ICANS | ||
| 0 | 7 | 70 |
| 1 | 2 | 20 |
| 2 | 0 | 0 |
| 3 | 1 | 10 |
| 4 | 0 | 0 |
| HLH | ||
| Yes | 0 | 0 |
| No | 10 | 100 |
| Tocilizumab | ||
| Yes | 5 | 50 |
| No | 5 | 50 |
| Steroid use | ||
| Yes | 5 | 50 |
| No | 5 | 50 |
| Anakinra | ||
| Yes | 0 | 0 |
| No | 10 | 100 |
| Delayed Parkinsonian neurotoxicity | ||
| Yes | 0 | 0 |
| No | 10 | 100 |
| Delayed non-Parkinsonian neurotoxicity | ||
| Yes∗ | 2 | 20 |
| No | 8 | 80 |
| Treatment of delayed neurotoxicity | ||
| Steroids | 1 | 10 |
| Steroids followed by pembrolizumab (PML due to JC virus),17 followed by investigational therapy on clinical trial | 1 | 10 |
| Infections | ||
| Yes | 5 | 50 |
| No | 5 | 50 |
HLH, Hemophagocytic lymphohistiocytosis; PML, Progressive Multifocal Leukoencephalopathy.
One patient had delayed lethargy and another patient had progressive multifocal leukoencephalopathy. Refer to text regarding their management and outcome.